Industry > Industry monitor > Pharmaceuticals
23 April 2021
The Drug Controller General of India (DCGI) has granted Restricted Emergency Use Approval for Zydus Cadila’s Pegylated Interferon alpha-2b (PegIFN) or `Virafin’ for treating moderate Covid-19 infection in adults.
A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during Covid, Virafin will help patients recover faster and avoid much of the complications, the company stated in a release.
Virafin will be available on the prescription of medical specialist for use in hospital/institutional setup.
In the multicentric trial conducted in 20-25 centers across India, Virafin had shown lesser need for supplemental oxygen, clearly indicating that it was able to control respiratory distress and failure which has been one of the major challenges in treating Covid-19. The drug has also shown efficacy against other viral infections.
Zydus
In a big boost to the national effort against COVID-19, Ahmedabad-based pharmaceutical major Zydus Cadila on Friday (23 April) announced that the company has received Restricted Emergency Use Approval (EUA) from the Drug Controller General of India (DCGI) for the use of âVirafinâ, Pegylated Interferon alpha-2b (PegIFN,) in treating moderate COVID-19 infection in adults.
The company has claimed that a single dose subcutaneous regimen of the Virafin developed by it can help patients recover faster and avoid complications if the drug is administered to them early on during COVID-19. In the multicentric trial conducted in 20-25 centers across India, Virafin had shown lesser need for supplemental oxygen, clearly indicating that it was able to control respiratory distress and failure which has been one of the major challenges in treating COVID-19, Zydus Cadila said in a statement.
DCGI gives EUA to Zydus for using Virafin on COVID-19 patients
DCGI gives EUA to Zydus for using Virafin on COVID-19 patients
23 April 2021 | News A single dose of the antiviral Virafin administered subcutaneously early on shows
significant clinical and virological improvement in moderate COVID-19 adult patients
Image credit- shutterstock.com
Zydus Cadila ha announced that the company has received Restricted Emergency Use Approval (EUA) from the Drug Controller General of India (DCGI) for the use of ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults.
A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID, Virafin will help patients recover faster and avoid much of the complications. Virafin will be available on the prescription of medical specialist for use in hospital/institutional setup.
April 23, 2021
Company claims the treatment reduces the hours of supplemental oxygen in the patients Cadila Healthcare Limited (Zydus Cadila) has received Restricted Emergency Use Approval from the Drug Controller General of India (DCGI) for the use of ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) in treating moderate Covid-19 infection in adults.
Announcing the development, the company informed that the single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients.
“When administered early on during Covid, Virafin will help patients recover faster and avoid much of the complications,” it said.
Virafin will be available on the prescription of medical specialist for use in hospital/institutional set-up.
Zydus Cadila receives Emergency Use Approval for Virafin business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.